ArticlePlastic and reconstructive surgery. Global open2026
Enhancing Recovery After Endoscopic Carpal Tunnel Release: The Role of Neurotrophic Supplementation.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assesses the role of neurotrophic supplementation on clinical and neurophysiological recovery in patients undergoing endoscopic carpal tunnel release (ECTR) for severe carpal tunnel syndrome (CTS). Methods: A total of 291 patients with severe CTS (visual analog scale [VAS] nocturnal pain ≥7, VAS function ≤ 4, and sensory conduction velocity [SCV] < 35 m/s) were retrospectively analyzed. Patients treated after March 2023 received neurotrophic supplementation for 6 months (E + N group, n = 172); those treated previously received ECTR alone (E group, n = 119). SCV and VAS scores were assessed at baseline and at 1, 3, 6, and 12 months. Upper limb disability was additionally evaluated using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire at the same time points. Statistical comparisons were performed using post hoc Tukey tests and χ Results: The E + N group showed improvement in SCV and VAS scores at 1 and 3 months ( Conclusions: Neurotrophic supplementation after ECTR accelerates early functional and electrophysiological recovery in severe CTS without increasing complications. Although long-term outcomes are similar, early recovery advantages support its use in selected patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.